INS and type 2 diabetes mellitus: While osteocalcin is not yet available as an adjunct pharmaceutical agent for metabo-glycemic regulation, including T2DM, it is being actively investigated in clinical trials 50; our data here strongly supports the continuing evaluation of this hormone in improving insulin action and restoring beta cell function under conditions of metabolic stress by proposing a mechanism of action.